The delay between the indication and the embodiment of the procedure decrease the effectiveness of percutaneous aortic valve replacement

Original title: Impact of wait times on the effectiveness of transcatheter aortic-valve replacement (TAVR) in severe aortic valve disease: a discrete event simulation model. Reference: Wijeysundera HC et al. Can J Cardiol. 2014; Epub ahead of print.

Once patients are accepted for percutaneous aortic valve replacement (TAVR), the higher the expected for the valve, the greater the risk of dying by peri-procedure or within a year.

In the PARTNER A study that used the Edwards Sapien balloon expandable valve a mathematical model to simulate the death risk was applied, according to the time elapsed (from 10 days to 180 days) while completing diagnostic studies to accept it as TAVR candidate and the time at which the procedure was performed. The daily risk of dying both peri-procedure or within one year post implant, increased progressively with longer waiting time, showing a difference of up to 27% between the longest and shortest waiting time for inoperable patients (10 day waiting time 1.9% risk, 60 days 10.7%, and 180 days 28.9%) and up to 20% of difference in high-risk patients (10 days 2.2% risk, 60 days 8.1% and 180 days 22.4%).

In contrast to this, waiting time and death risk were relatively stable for those who received medical treatment or surgery, respectively. In the inoperable cohort, most patients receiving TAVR (99.2%) had lower mortality than those receiving medical treatment beyond what they had to wait for the procedure. In the high-risk cohort, when the waiting time exceeded 60 days, patients receiving TAVR showed higher mortality than those receiving surgery. With longer waits for 180 days, non-inferiority between TAVR and proven surgery in PARTNER A study missed almost half of the patients.

Conclusion

Modest increases in waiting time to percutaneous aortic valve replacement have a significant impact on mortality in the inoperable cohort as well as in the high-risk cohort.

Editorial comment

The findings of this study are particularly important for those patients who might be candidates for surgery so as to TVAR, since the loss of time could tip the balance in favour of surgery. 

SOLACI.ORG

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....